Jan 5 Halozyme Therapeutics Inc said
its lead drug to treat a late form of pancreated cancer met the
main goal in a mid-stage study, sending its shares soaring in
The study population showed a statistically significant
increase in progression-free survival, the company said.
Pancreatic cancer is the third-leading cause of
cancer-related death in the United States.
Halozyme's shares were up 44 percent at $15.40 in trading
before the opening bell on Thursday.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by